PHILADELPHIA, Oct. 08, 2025 (GLOBE NEWSWIRE) --

Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX):

Grabar Law Office is investigating claims on behalf of shareholders of Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX) as securities fraud class action survives a motion to dismiss. The investigation concerns whether certain officers and directors breached the fiduciary duties they owed to the company.

If you purchased Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX) prior to May 11, 2023, and still hold shares today, you can seek corporate reforms, the return of funds back to the company, and a court approved incentive award at no cost to you whatsoever.  
Please visit https://grabarlaw.com/the-latest/amylyx-shareholder-investigation/, contact Joshua Grabar at jgrabar@grabarlaw.com, or call 267-507-6085.
  
WHY? Key allegations of a recently filed securities fraud class action complaint filed against Amylyx Pharmaceuticals, Inc., (NASDAQ: AMLX) and certain of its officers, have now survived a motion to dismiss.

The underlying securities fraud class action complaint alleges that, Amylyx Pharmaceuticals, Inc., through certain of its officers and directors, made materially false and misleading statements regarding the Company’s business, operations, and prospects in that: (i) Defendants had overstated Relyvrio’s commercial prospects; (ii) patients were discontinuing treatment with Relyvrio after six months; (iii) the rate at which new patients were starting treatment with Relyvrio was decreasing; (iv) accordingly, Defendants had also overstated Relyvrio’s prescription rate; (v) Defendants attempted to hide the foregoing negative trends from investors and the market by blocking analysts from viewing Relyvrio’s prescription data; and (vi) as a result, Defendants’ public statements were materially false and misleading at all relevant times. Then on April 4, 2024, Amylyx announced it was pulling Relyvrio from the market.

On September 30, 2025, the court determined that certain key allegations survived the defendants’ motion to dismiss the underlying class action complaint.

WHAT YOU CAN DO NOW: If you purchased Amylyx Pharmaceuticals, Inc., (NASDAQ: AMLX) prior to May 11, 2023, and still hold shares today, you are encouraged to visit https://grabarlaw.com/the-latest/amylyx-shareholder-investigation/, contact Joshua Grabar at jgrabar@grabarlaw.com, or call 267-507-6085. You can seek corporate reforms, the return of funds back to the company, and a court approved incentive award at no cost to you whatsoever. $AMLX #Amylyx #AMLX

Humana Inc. (NYSE: HUM):

Grabar Law Office is investigating claims on behalf of shareholders of Humana Inc. (NYSE: HUM). The investigation concerns whether certain officers and directors breached the fiduciary duties they owed to the company.

If you purchased Humana Inc. (NYSE: HUM), shares prior to December July 27, 2022, and still hold shares today, you can seek corporate reforms, the return of funds back to the company, and a court approved incentive award at no cost to you whatsoever.
Please visit https://grabarlaw.com/the-latest/humana-shareholder-investigation/, contact Joshua Grabar at jgrabar@grabarlaw.com, or call 267-507-6085 to learn more.

WHY? As alleged in a recently filed federal securities fraud class action complaint, Humana Inc. (NYSE: HUM), through certain of its officers, made materially false and/or misleading statements, as well as failed to disclose material adverse facts, about the Company’s business and operations. Specifically, the Complaint alleges Defendants downplayed pressures on the Company’s adjusted EPS resulting from increased medical costs associated with pent-up demand for healthcare procedures (especially as COVID concerns abated) which, contrary to the Company’s assurances, resulted in increased utilization rates and costs.

WHAT YOU CAN DO NOW: If you purchased Humana Inc. (NYSE: HUM), shares prior to December July 27, 2022, and still hold shares today, you are encouraged to visit https://grabarlaw.com/the-latest/humana-shareholder-investigation/, contact Joshua Grabar at jgrabar@grabarlaw.com, or call 267-507-6085. You can seek corporate reforms, the return of funds back to the company, and a court approved incentive award at no cost to you whatsoever. #HUM $HUM #Humana

Unicycive Therapeutics, Inc. (NASDAQ: UNCY):

Grabar Law Office is investigating claims on behalf of shareholders of Unicycive Therapeutics, Inc. (NASDAQ: UNCY). The investigation concerns whether certain officers and directors breached the fiduciary duties they owed to the company.

If you purchased Unicycive Therapeutics, Inc. (NASDAQ: UNCY) shares prior to March 29, 2024, and still hold shares today, you can seek corporate reforms, the return of funds back to the company, and a court approved incentive award at no cost to you whatsoever. Alternatively, if you purchased Unicycive shares between March 29, 2024 and June 27, 2025, you can participate in the class action. Please visit https://grabarlaw.com/the-latest/unicycive-shareholder-investigation/, contact Joshua Grabar at jgrabar@grabarlaw.com, or call 267-507-6085 to learn more.

WHY: As alleged in a recently filed federal securities fraud class action complaint, Unicycive Therapeutics, Inc. (NASDAQ: UNCY), through certain of its officers, made false statements and/or concealed that: (i) Unicycive's readiness and ability to satisfy the FDA's manufacturing compliance requirements was overstated; (ii) the oxylanthanum carbonate new drug application's regulatory prospects were likewise overstated; and (iii) as a result, defendants' public statements were materially false and misleading at all relevant times.

WHAT YOU CAN DO NOW: If you purchased Unicycive Therapeutics, Inc. (NASDAQ: UNCY), shares prior to March 29, 2024, and still hold shares today, you are encouraged to visit https://grabarlaw.com/the-latest/unicycive-shareholder-investigation/, contact Joshua Grabar at jgrabar@grabarlaw.com, or call 267-507-6085. You can seek corporate reforms, the return of funds back to the company, and a court approved incentive award at no cost to you whatsoever. Alternatively, if you purchased Unicycive shares between March 29, 2024 and June 27, 2025, you can participate in the class action. $UNCY #Unicycive

Vestis Corp. (NYSE: VSTS) – Securities Fraud Class Action Survives Motion to Dismiss:

Grabar Law Office is investigating claims on behalf of shareholders of Vestis Corp. (NYSE: VSTS). The investigation concerns whether certain officers and directors breached the fiduciary duties they owed to the company.

If you acquired Vestis (NYSE: VSTS), shares on or near October 2, 2023, as a result of the Aramark spinoff, and still hold shares today, you can seek corporate reforms, the return of funds back to the company, and a court approved incentive award at no cost to you whatsoever. Please visit https://grabarlaw.com/the-latest/vestis-shareholder-investigation/, contact Joshua Grabar at jgrabar@grabarlaw.com, or call 267-507-6085.

WHY? According to an underlying federal securities fraud class action complaint, Vestis Corporation (NYSE: VSTS), through certain of its officers, made materially false and misleading statements and failed to disclose that: (1) Aramark had historically underinvested in the business that became Vestis; (2) Vestis operated with outdated facilities and an underperforming sales force; (3) Vestis’s outdated facilities and underperforming sales force led to “service gaps” that had impeded the Company’s levers of growth and had resulted in customer attrition; and (4) as a result of the above, Defendants’ statements about Vestis’s business, operations, and prospects were materially false and misleading and/or lacked a reasonable basis at all relevant times. Shares of Vestis fell about 45% on May 2, 2024, when the company announced, "results in the quarter and our outlook for the year are not in line with expectations.”

On September 30, 2025, key allegations in the securities fraud class action survived defendants’ attempts to dismiss the complaint. U.S. District Judge Steven D. Grimberg largely denied a pair of dismissal bids, finding, among other things, that certain statements made by the defendants as ahead of the spinoff were clearly material to investors and couldn't be considered inactionable puffery. According to the Judge: "It is self-evident that the alleged statements were made at too pivotal of a moment (during the spinoff), about topics too essential to Vestis's business (customer service and retention), to be ruled immaterial to all reasonable investors as a matter of law."

WHAT YOU CAN DO NOW: If you acquired Vestis (NYSE: VSTS), shares on or near October 2, 2023, through the Aramark spinoff, and still hold shares today, you are encouraged to visit https://grabarlaw.com/the-latest/vestis-shareholder-investigation/, contact Joshua Grabar at jgrabar@grabarlaw.com, or call 267-507-6085. You can seek corporate reforms, the return of funds back to the company, and a court approved incentive award at no cost to you whatsoever. #VSTS $VSTS #Vestis $ARMK #Aramark

Attorney Advertising Disclaimer

Contact:
Joshua H. Grabar, Esq.
Grabar Law Office
One Liberty Place
1650 Market Street, Suite 3600
Philadelphia, PA 19103
Tel:  267-507-6085
Email: jgrabar@grabarlaw.com